Kailera Therapeutics (KLRA) Competitors $19.62 +0.07 (+0.36%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock KLRA vs. ABVX, PRAX, CYTK, KRYS, and IBRXShould you buy Kailera Therapeutics stock or one of its competitors? MarketBeat compares Kailera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kailera Therapeutics include Abivax (ABVX), Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), Krystal Biotech (KRYS), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. KLRA vs. ABVXKLRA vs. PRAXKLRA vs. CYTKKLRA vs. KRYSKLRA vs. IBRXHow does Kailera Therapeutics compare to Abivax?Kailera Therapeutics (NASDAQ:KLRA) and Abivax (NASDAQ:ABVX) are both mid-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability. Which has higher earnings & valuation, KLRA or ABVX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKailera TherapeuticsN/AN/AN/AN/AN/AAbivaxN/AN/A-$380.27M-$5.37N/A Do insiders & institutionals believe in KLRA or ABVX? 47.9% of Abivax shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer KLRA or ABVX? In the previous week, Kailera Therapeutics had 5 more articles in the media than Abivax. MarketBeat recorded 8 mentions for Kailera Therapeutics and 3 mentions for Abivax. Kailera Therapeutics' average media sentiment score of 0.73 beat Abivax's score of -0.09 indicating that Kailera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer KLRA or ABVX? Kailera Therapeutics presently has a consensus price target of $42.75, indicating a potential upside of 117.89%. Abivax has a consensus price target of $137.15, indicating a potential upside of 20.60%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kailera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Abivax 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.93 Is KLRA or ABVX more profitable? Kailera Therapeutics' return on equity of 0.00% beat Abivax's return on equity.Company Net Margins Return on Equity Return on Assets Kailera TherapeuticsN/A N/A N/A Abivax N/A -146.43%-88.69% SummaryKailera Therapeutics beats Abivax on 6 of the 8 factors compared between the two stocks.How does Kailera Therapeutics compare to Praxis Precision Medicines?Kailera Therapeutics (NASDAQ:KLRA) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings. Do analysts rate KLRA or PRAX? Kailera Therapeutics presently has a consensus target price of $42.75, suggesting a potential upside of 117.89%. Praxis Precision Medicines has a consensus target price of $592.67, suggesting a potential upside of 84.86%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kailera Therapeutics is more favorable than Praxis Precision Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kailera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Praxis Precision Medicines 2 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 4 Strong Buy rating(s) 2.95 Is KLRA or PRAX more profitable? Kailera Therapeutics' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Kailera TherapeuticsN/A N/A N/A Praxis Precision Medicines N/A -43.02%-40.22% Do insiders & institutionals hold more shares of KLRA or PRAX? 67.8% of Praxis Precision Medicines shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher earnings and valuation, KLRA or PRAX? Kailera Therapeutics has higher earnings, but lower revenue than Praxis Precision Medicines. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKailera TherapeuticsN/AN/AN/AN/AN/APraxis Precision Medicines$8.55M1,045.45-$303.27M-$13.37N/A Does the media prefer KLRA or PRAX? In the previous week, Kailera Therapeutics had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 8 mentions for Kailera Therapeutics and 6 mentions for Praxis Precision Medicines. Kailera Therapeutics' average media sentiment score of 0.73 beat Praxis Precision Medicines' score of -0.05 indicating that Kailera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryKailera Therapeutics beats Praxis Precision Medicines on 6 of the 11 factors compared between the two stocks.How does Kailera Therapeutics compare to Cytokinetics?Kailera Therapeutics (NASDAQ:KLRA) and Cytokinetics (NASDAQ:CYTK) are both mid-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations. Do analysts prefer KLRA or CYTK? Kailera Therapeutics currently has a consensus price target of $42.75, suggesting a potential upside of 117.89%. Cytokinetics has a consensus price target of $99.30, suggesting a potential upside of 29.89%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kailera Therapeutics is more favorable than Cytokinetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kailera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Cytokinetics 1 Sell rating(s) 3 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.82 Which has better valuation & earnings, KLRA or CYTK? Kailera Therapeutics has higher earnings, but lower revenue than Cytokinetics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKailera TherapeuticsN/AN/AN/AN/AN/ACytokinetics$88.04M108.05-$784.96M-$6.84N/A Is KLRA or CYTK more profitable? Kailera Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Company Net Margins Return on Equity Return on Assets Kailera TherapeuticsN/A N/A N/A Cytokinetics -784.02%N/A -52.86% Does the media prefer KLRA or CYTK? In the previous week, Cytokinetics had 8 more articles in the media than Kailera Therapeutics. MarketBeat recorded 16 mentions for Cytokinetics and 8 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.73 beat Cytokinetics' score of 0.54 indicating that Kailera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKailera Therapeutics beats Cytokinetics on 5 of the 8 factors compared between the two stocks.How does Kailera Therapeutics compare to Krystal Biotech?Kailera Therapeutics (NASDAQ:KLRA) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Do insiders & institutionals hold more shares of KLRA or KRYS? 86.3% of Krystal Biotech shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, KLRA or KRYS? Krystal Biotech has higher revenue and earnings than Kailera Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKailera TherapeuticsN/AN/AN/AN/AN/AKrystal Biotech$389.13M22.22$204.83M$7.4839.21 Does the media favor KLRA or KRYS? In the previous week, Kailera Therapeutics and Kailera Therapeutics both had 8 articles in the media. Kailera Therapeutics' average media sentiment score of 0.73 beat Krystal Biotech's score of 0.45 indicating that Kailera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate KLRA or KRYS? Kailera Therapeutics currently has a consensus target price of $42.75, indicating a potential upside of 117.89%. Krystal Biotech has a consensus target price of $324.11, indicating a potential upside of 10.50%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Kailera Therapeutics is more favorable than Krystal Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kailera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Krystal Biotech 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is KLRA or KRYS more profitable? Krystal Biotech has a net margin of 53.92% compared to Kailera Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Kailera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kailera TherapeuticsN/A N/A N/A Krystal Biotech 53.92%19.25%17.62% SummaryKrystal Biotech beats Kailera Therapeutics on 7 of the 11 factors compared between the two stocks.How does Kailera Therapeutics compare to ImmunityBio?Kailera Therapeutics (NASDAQ:KLRA) and ImmunityBio (NASDAQ:IBRX) are both mid-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Is KLRA or IBRX more profitable? Kailera Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. Company Net Margins Return on Equity Return on Assets Kailera TherapeuticsN/A N/A N/A ImmunityBio -606.15%N/A -59.53% Do analysts prefer KLRA or IBRX? Kailera Therapeutics presently has a consensus target price of $42.75, indicating a potential upside of 117.89%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 82.99%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Kailera Therapeutics is more favorable than ImmunityBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kailera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00ImmunityBio 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Does the media favor KLRA or IBRX? In the previous week, ImmunityBio had 35 more articles in the media than Kailera Therapeutics. MarketBeat recorded 43 mentions for ImmunityBio and 8 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.73 beat ImmunityBio's score of 0.16 indicating that Kailera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 3 Very Positive mention(s) 2 Positive mention(s) 33 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Which has better earnings & valuation, KLRA or IBRX? Kailera Therapeutics has higher earnings, but lower revenue than ImmunityBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKailera TherapeuticsN/AN/AN/AN/AN/AImmunityBio$113.29M71.74-$351.40M-$0.85N/A Do institutionals & insiders believe in KLRA or IBRX? 8.6% of ImmunityBio shares are held by institutional investors. 69.5% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryKailera Therapeutics beats ImmunityBio on 5 of the 9 factors compared between the two stocks. Get Kailera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KLRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLRA vs. The Competition ExportMetricKailera TherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$2.43B$922.46M$4.14B$12.10BDividend YieldN/A4.84%6.12%5.32%P/E RatioN/A1.4922.6525.09Price / SalesN/A116.61112.3691.07Price / CashN/A20.0750.5337.30Price / BookN/A8.2237.626.60Net IncomeN/A-$3.49M$113.56M$335.71M7 Day Performance-12.02%4.24%-0.75%-2.03%1 Month PerformanceN/A69.75%-0.67%-1.90%1 Year PerformanceN/A124.01%13.72%27.36% Kailera Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLRAKailera Therapeutics4.9295 of 5 stars$19.62+0.4%$42.75+117.9%N/A$2.43BN/AN/A145Short Interest IncreaseABVXAbivax3.1784 of 5 stars$122.74-1.5%$137.15+11.7%+1,789.4%$9.88BN/AN/A61Upcoming EarningsPRAXPraxis Precision Medicines3.1721 of 5 stars$330.02-1.0%$591.83+79.3%+765.8%$9.29B$8.55MN/A110CYTKCytokinetics2.9268 of 5 stars$76.91+3.5%$97.25+26.4%+142.5%$9.24B$88.04MN/A250Analyst ForecastKRYSKrystal Biotech2.8253 of 5 stars$305.71+3.0%$324.11+6.0%+123.4%$8.75B$389.13M40.87210Analyst Forecast Related Companies and Tools Related Companies ABVX Alternatives PRAX Alternatives CYTK Alternatives KRYS Alternatives IBRX Alternatives NUVL Alternatives PCVX Alternatives KYMR Alternatives QGEN Alternatives RYTM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLRA) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kailera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kailera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
